KathleenAnneNevilleMDMS, MBA

Clinical Trials

• Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma Start of enrollment: 2008 Jan 14

  Completed

  Phase 2

• External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas Start of enrollment: 2009 Oct 30

  Completed

  Phase 2

• Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22

  Completed

  Phase 2

• Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Start of enrollment: 2011 Feb 09

  Completed

  Phase 1, Phase 2

• Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets Start of enrollment: 2011 Jul 01

  Completed

• A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL Start of enrollment: 2011 Dec 01

  Terminated

  Phase 1, Phase 2

• Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma Start of enrollment: 2011 Dec 01

  Terminated

  Phase 1, Phase 2

• Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma Start of enrollment: 2011 Dec 01

  Completed

  Phase 2

• Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma Start of enrollment: 2011 Dec 01

  Terminated

  Phase 1, Phase 2

• Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission Start of enrollment: 2012 Jun 01

  Active, not recruiting

  Phase 2

• A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) Start of enrollment: 2013 May 06

  Completed

  Phase 2

• Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12

  Completed

  Phase 2

• Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer Start of enrollment: 2013 Mar 04

  Completed

  Not Applicable

• Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. Start of enrollment: 2013 Aug 20

  Completed

  Phase 2

• Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma Start of enrollment: 2014 Jun 06

  Completed

  Phase 1, Phase 2

• Molecular-Guided Therapy for Childhood Cancer Start of enrollment: 2014 Jul 08

  Completed

  Not Applicable

• Trial of Tolcapone With Oxaliplatin for Neuroblastoma Start of enrollment: 2015 Dec 01

  Terminated

  Phase 1

• Neuroblastoma Maintenance Therapy Trial Start of enrollment: 2016 Feb 01

  Recruiting

  Phase 2

• Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma Start of enrollment: 2020 Sep 25

  Recruiting

  Phase 2

• Join now to see all